Role of P2Y Receptors in Platelet Extracellular Vesicle Release

Int J Mol Sci. 2020 Aug 23;21(17):6065. doi: 10.3390/ijms21176065.


Platelet extracellular vesicles (PEVs) are potential new biomarkers of platelet activation which may allow us to predict and/or diagnose developing coronary thrombosis before myocardial necrosis occurs. The P2Y1 and P2Y12 receptors play a key role in platelet activation and aggregation. Whereas the P2Y1 antagonists are at the preclinical stage, at present, the P2Y12 antagonists are the most effective treatment strategy to prevent stent thrombosis after percutaneous coronary intervention. Despite an increasing number of publications on PEVs, the mechanisms underlying their formation, including the role of purinergic receptors in this process, remain an active research field. Here, we outline the clinical relevance of PEVs in cardiovascular disease, summarize the role and downstream signalling of P2Y receptors in platelet activation, and discuss the available evidence regarding their role in PEV formation.

Keywords: P2Y1 receptors; P2Y12 receptors; antiplatelet therapy; clopidogrel; extracellular vesicles; ticagrelor.

Publication types

  • Review

MeSH terms

  • Animals
  • Blood Platelets / cytology*
  • Blood Platelets / metabolism
  • Cardiovascular Diseases / diagnosis*
  • Cardiovascular Diseases / therapy
  • Extracellular Vesicles / metabolism*
  • Humans
  • Platelet Activation
  • Prognosis
  • Receptors, Purinergic P2Y / metabolism*
  • Signal Transduction


  • Receptors, Purinergic P2Y